



Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort

Alexandra de Sitter¹ · Tom Verhoeven¹ · Jessica Burggraaff² · Yaou Liu¹ · Jorge Simoes¹ · Serena Ruggieri^{3,4} · Miklos Palotai⁵ · Iman Brouwer¹ · Adriaan Versteeg¹ · Viktor Wottschel¹ · Stefan Ropele⁶ · Mara A. Rocca^{7,8} · Claudio Gasperini⁴ · Antonio Gallo⁹ · Marios C. Yiannakas¹⁰ · Alex Rovira¹¹ · Christian Enzinger¹² · Massimo Filippi^{7,8,13,14} · Nicola De Stefano¹⁵ · Ludwig Kappos¹⁶ · Jette L. Frederiksen¹⁷ · Bernard M. J. Uitdehaag² · Frederik Barkhof^{1,18} · Charles R. G. Guttmann⁵ · Hugo Vrenken¹ · the MAGNIMS Study Group

Received: 4 May 2020 / Revised: 22 June 2020 / Accepted: 23 June 2020
© The Author(s) 2020

Abstract

Background Deep grey matter (DGM) atrophy in multiple sclerosis (MS) and its relation to cognitive and clinical decline requires accurate measurements. MS pathology may deteriorate the performance of automated segmentation methods. Accuracy of DGM segmentation methods is compared between MS and controls, and the relation of performance with lesions and atrophy is studied.

Methods On images of 21 MS subjects and 11 controls, three raters manually outlined caudate nucleus, putamen and thalamus; outlines were combined by majority voting. FSL-FIRST, FreeSurfer, Geodesic Information Flow and volBrain were evaluated. Performance was evaluated volumetrically (intra-class correlation coefficient (ICC)) and spatially (Dice similarity coefficient (DSC)). Spearman's correlations of DSC with global and local lesion volume, structure of interest volume (ROIV), and normalized brain volume (NBV) were assessed.

Results ICC with manual volumes was mostly good and spatial agreement was high. MS exhibited significantly lower DSC than controls for thalamus and putamen. For some combinations of structure and method, DSC correlated negatively with lesion volume or positively with NBV or ROIV. Lesion-filling did not substantially change segmentations.

Conclusions Automated methods have impaired performance in patients. Performance generally deteriorated with higher lesion volume and lower NBV and ROIV, suggesting that these may contribute to the impaired performance.

Keywords Multiple sclerosis · Deep grey matter · Atrophy · Automated segmentation methods

Introduction

In multiple sclerosis (MS), atrophy of deep grey matter (DGM) structures like the caudate nucleus (caudate), putamen and thalamus is associated with cognitive and clinical

impairment [1–4]. Accurate segmentations of these structures from structural MRI are key to understanding these atrophic processes and their role in MS.

However, it is unclear whether DGM segmentation using state-of-the-art automated methods is as accurate in MS cases as in healthy controls. Since studies have shown that white matter (WM) lesions and atrophy could affect measures such as whole-brain grey matter (GM) volume, it could be expected that such pathology also affects DGM segmentation [1, 5–9].

A direct comparison of automated methods to expert manual (reference) segmentation was performed by Derakhshan et al. (2010) in a small dataset containing 3 slices each of 3 MS patients [1]. Although that paper provided insights into the spatial overlap between automated and

Alexandra de Sitter and Tom Verhoeven contributed equally.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00415-020-10023-1>) contains supplementary material, which is available to authorized users.

✉ Alexandra de Sitter
A.deSitter@amsterdamumc.nl

Extended author information available on the last page of the article

manual segmentations, with 3 slices per subject no volumetric analysis was possible. Moreover, the small number of subjects did not allow any analysis of relations between segmentation performance and MS-related pathological changes.

Therefore, this study quantitatively investigated automated segmentation performance in a whole-brain dataset of 32 subjects including MS patients and healthy controls. Four publicly available segmentation method packages (FSL-FIRST [10], FreeSurfer [11], Geodesic Information Flow (GIF) [12] and volBrain [13]) were evaluated in terms of volumetric and spatial agreement with manual segmentations created by combining manual outlines of three trained raters by majority voting. Moreover, the relation of segmentation accuracy with total and regional lesion load, whole-brain volume, and volume of the structure of interest was assessed to determine possible confounding disease relations factors.

Methods

Subjects

In total 21 MS patients and 11 healthy controls subjects were retrospectively selected from two of the multi-center studies of the MAGNIMS Study Group (www.magnims.eu) [14, 15]. Demographic details of the subjects are listed in Table 1. Subjects had been recruited at nine European centers, see Supplementary data A for the centers.

The selection of the cases was based on maximizing the number of scanners and the number of secondary progressive MS (SPMS) and primary progressive MS (PPMS) cases while considering the workload for the three raters. All patients and controls had given informed consent for the use of their brain MRI-scans for research within the original study.

Table 1 Demographics of the subjects

Disease status	Number of cases (male/female)	Average age in years \pm std	Median EDSS score (range)	Average DD year \pm std
HC	11 (3/8)	37.6 \pm 8.2	n.a	n.a
MS	21 (9/12)	43.2 \pm 10.1	3.5 (6.0)	9.5 \pm 6.9
RRMS	10 (4/6)	39.8 \pm 8.3	2.3 (2.5)	8.0 \pm 9.8
SPMS	5 (3/2)	41.3 \pm 8.9	4.0 (6.0)	11.0 \pm 5.3
PPMS	6 (2/4)	49.4 \pm 10.8	3.5 (4.5)	14.0 \pm 4.0

EDSS expanded disability status scale, DD disease duration, std Standard deviation, HC healthy control, RR relapsing remitting, SP secondary progressive, PP primary progressive

Acquisition

An overview of acquisition parameters for each site is given in Supplementary Tables 1 and 2. Briefly, MRI data were obtained using magnets operating at 3 T for all cases with three vendors (Siemens, Philips and GE). One of the two following imaging protocols was used: (1) 3D T1-weighted scan (different pulse sequences for different vendors) and a dual-echo spin echo scan with both 2D T2-weighted and 2D proton density (PD) weighted; or (2) 3D T1-weighted magnetization prepared rapid gradient echo (MPRAGE) scan and 2D fluid-attenuated inversion recovery (FLAIR) T2-weighted fast spin-echo sequence.

Manual segmentation of DGM structures

Manual segmentation of three DGM structures was performed using the SPINE online environment for collaborative research (<https://spinevirtuallab.org>). The caudate nucleus, putamen and thalamus were all manually segmented on the full 3D T1-weighted images in each subject by each rater. Four scans were outlined a second time by each rater to examine intra-rater variability. A summary of the segmentation protocol is added to the supplementary data (Supplementary Protocol 1).

The manual segmentations of the three raters were combined into a reference using majority voting: i.e., a voxel was classified as part of a structure if at least 2 of the 3 raters assigned it to that structure.

Lesion segmentation

Lesion segmentation was also performed manually by one expert rater, on the FLAIR scan or on the PD scan. The lesion segmentation was performed using the Medical Image Processing, Analysis, and Visualization (MIPAV) software environment whereby only lesions of at least three voxels were included.

Lesion filling

Lesion-filling is a common pre-processing step in patient scans, in which the intensities of voxels identified as being part of WM lesions are replaced by intensities similar to normal-appearing white matter. In this study, lesion-filling was applied using two algorithms: lesion segmentation toolbox (LST-LF) [16], and LEAP [8], and both versions of lesion-filled images as well as native images were analyzed. The lesion masks were first co-registered from their original PD or FLAIR space to 3D-T1 space using FSL-FLIRT with tri-linear interpolation and a threshold of 0.5 because this

was previously found to provide good results for whole-brain GM volume measurements [6]. The Supplementary data B provides a description of LST-LF and LEAP. In this study, lesion-filling was applied using two algorithms: lesion segmentation toolbox (LST-LF) [16], and LEAP [8], and both versions of lesion-filled images as well as native images were analyzed. The lesion masks were first co-registered from their original PD or FLAIR space to 3D-T1 space using FSL-FLIRT with tri-linear interpolation and a threshold of 0.5, based on literature [6]. Second, the lesion was filled on the 3D-T1 weighted image with the use of the lesion mask in 3D-T1 space. The Supplementary data B provides a description of the two used lesion filling methods (LST-LF and LEAP).

Automatic DGM segmentation method

Within this study four automatic DGM segmentation methods were assessed; FSL-FIRST (<https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST>), FreeSurfer (<https://surfer.nmr.mgh.harvard.edu>), volBrain (<https://volBrain.upv.es>) and GIF (<https://niftyweb.cs.ucl.ac.uk>).

FSL-FIRST, version 6.0.1, has previously been described by Patenaude et al. (2011). In short, FSL-FIRST finds the most plausible outline based on the observed intensities from the T1-weighted input image using shape and appearance models derived from a large training dataset. Surface meshes of the subcortical structures were converted to boundary corrected voxelwise segmentations [10].

FreeSurfer, version 6.0.0, is described on the FreeSurfer-Wiki page (<https://surfer.nmr.mgh.harvard.edu/fswiki/>). In short, labels are assigned to each voxel in the subcortical region (WM + subcortical GM). From these segmentations, the binary segmentations for the individual structure were extracted [11].

Geodesic Information Flow (GIF), versions V2.0, uses manually created atlases for segmentation of the input

images. GIF captures the local variation in morphology and in standard space locations. With the use of an iterative geodesic minimization algorithm and the manual labels, more accurate segmentations are expected [12].

VolBrain, version 1.0 is an online pipeline for volumetric brain analysis. The proposed pipeline is based on a library of manually labeled atlas cases to perform the segmentation process, including subcortical structure segmentation as proposed by Coupé et al. 2011 [13, 17].

Brain volume

The normalized brain volume (NBV) and brain volume (BV) were measured with SIENAX (part of FSL version 5.0) [18] on the lesion filled data. SIENAX is the cross-sectional pipeline of the SIENA method [19]. Based on voxel intensities it estimates partial volume fractions of GM, WM and cerebrospinal fluid (CSF) for each voxel. Volumes of GM and WM were added to obtain BV. SIENAX performs normalization of skull size to MNI space to obtain NBV.

Relation with MS pathology

The association of automatic segmentation performance, as measured by Dice similarity coefficient (DSC, see statistical analyses section), with multiple MS-related disease parameters, i.e. WM lesion load, regional lesion load, normalized brain volume (NBV) and DGM structure volume, was investigated. WM lesion load was determined from the manual lesion outlines. Regional lesion load was evaluated by measuring the lesion load within a pre-defined distance from the DGM structure (see Fig. 1). Using the distance transform, the distance of each voxel to the reference of the structure in the specific subject under investigation was calculated. By thresholding of the subject- and structure-specific distance map and masking with the subject-specific WM mask obtained with FreeSurfer, for each case, a “surrounding




Fig. 1 Method for lesion load calculation within a set border. **a** a distance field is created around DGM structure, in this case the caudate nucleus. **b** Distance is set around the DGM structure, seen in grey. **c** An overlay is created between the DGM border and the lesion mask

in T1 space. In grey the lesion border is shown, in red the lesions without overlap with the border and in yellow the lesions with an overlap in the border

WM border" region at distances of 0–10 mm was defined. Region-specific lesion volumes were obtained by masking the WM lesion mask in 3D-T1 space with these WM surrounding WM border.

Statistical analyses

Intra-rater agreement was measured between the first and second manual segmentation of the structures with the Dice similarity coefficient (DSC) [20]:

$$DSC(A, B) = \frac{2(A \cap B)}{A + B}$$

with A and B defined as the segmentations and where \cap is the intersection of the two segmentations.

Volumetric analysis was done by comparing the volume of the reference with volumes of the automated segmentation. Moreover, the intra-class correlation coefficient (ICC) for the absolute agreement was calculated [21].

Spatial overlap between reference and the automated method was measured with DSC. Student's t test was used to compare DSC with the reference between controls and

patients. To assess the effect of lesion-filling, two-way ANOVA analysis was performed comparing DSC of native images separately with those from each of the two lesion-filling methods (LEAP and LST).

The relation of disease pathology with spatial performance was examined using Spearman's correlation coefficient, in which $0.0 < |r| < 0.2$ was considered a weak correlation, $0.2 \leq |r| < 0.5$ a moderate correlation and $|r| \geq 0.5$ a strong correlation [22].

For all statistical analysis P -values < 0.05 were considered statistically significant.

Results

Manual segmentation

Volumes of the reference DGM structures are listed in Table 2. Intra-rater agreement was assessed through DSC means per structure for three cases (Table 3). Intra-rater DSC was consistently high, with $DSC \geq 0.85$ for all the experts across all six DGM structures. No difference in inter-rater DSC was observed between raters or between DGM

Table 2 For all structures and hemispheres, first the mean volume \pm standard deviation (std) in millimeter of reference and the four automated segmentation software

Method $N=32$	Left Caudate			Right Caudate		
	Volume	ICC	DSC	Volume	ICC	DSC
Reference	3.99 \pm 0.64			3.98 \pm 0.60		
FSL-FIRST	3.46 \pm 0.45	0.69	0.84 \pm 0.04	3.53 \pm 0.49	0.81	0.84 \pm 0.04
FreeSurfer	3.55 \pm 0.52	0.74	0.76 \pm 0.09	3.75 \pm 0.58	0.68	0.77 \pm 0.09
GIF	3.52 \pm 0.42	0.50	0.83 \pm 0.04	3.73 \pm 0.47	0.60	0.83 \pm 0.05
volBrain	3.55 \pm 0.55	0.85	0.83 \pm 0.07	3.57 \pm 0.54	0.86	0.83 \pm 0.07
	Left Putamen			Right Thalamus		
	Volume	ICC	DSC	Volume	ICC	DSC
Reference	4.79 \pm 0.79			4.65 \pm 0.73		
FSL-FIRST	4.85 \pm 0.73	0.94	0.88 \pm 0.03	4.83 \pm 0.79	0.93	0.87 \pm 0.04
FreeSurfer	4.60 \pm 0.88	0.94	0.81 \pm 0.08	4.66 \pm 0.88	0.96	0.81 \pm 0.07
GIF	4.37 \pm 0.70	0.98	0.80 \pm 0.03	4.34 \pm 0.65	0.92	0.81 \pm 0.03
volBrain	4.09 \pm 0.65	0.77	0.84 \pm 0.06	4.04 \pm 0.60	0.80	0.84 \pm 0.06
	Left Thalamus			Right Thalamus		
	Volume	ICC	DSC	Volume	ICC	DSC
Reference	6.83 \pm 1.19			6.80 \pm 1.21		
FSL-FIRST	7.87 \pm 1.01	0.76	0.82 \pm 0.05	7.69 \pm 0.98	0.79	0.83 \pm 0.05
FreeSurfer	7.32 \pm 1.10	0.80	0.77 \pm 0.08	6.93 \pm 1.01	0.95	0.78 \pm 0.08
GIF	5.81 \pm 0.76	0.72	0.77 \pm 0.04	5.67 \pm 0.68	0.64	0.76 \pm 0.04
volBrain	5.47 \pm 1.01	0.68	0.80 \pm 0.07	5.39 \pm 0.98	0.67	0.80 \pm 0.07

Second, the intra-class correlation coefficient (ICC) and mean dice similarity coefficient (DSC) \pm std between the reference and the segmentation of the automated segmentation software. N =amount of subjects

Table 3 For all structures and hemispheres the spatial overlap of intra rater agreement. Spatial overlap is shown with the mean dice similarity coefficient \pm standard deviation and is calculated over four subjects

Rater	Left caudate	Right caudate	Left putamen	Right putamen	Left thalamus	Right thalamus
Expert 1	0.87 \pm 0.031	0.87 \pm 0.037	0.89 \pm 0.047	0.91 \pm 0.026	0.87 \pm 0.035	0.88 \pm 0.007
Expert 2	0.87 \pm 0.051	0.88 \pm 0.032	0.85 \pm 0.039	0.88 \pm 0.018	0.89 \pm 0.031	0.88 \pm 0.022
Expert 3	0.92 \pm 0.004	0.92 \pm 0.008	0.91 \pm 0.022	0.92 \pm 0.016	0.89 \pm 0.022	0.91 \pm 0.008

Table 4 The average (\pm standard deviation) amount of voxels that were selected by one rater for both healthy control groups (HC) as patients (MS) group

Structure	HC ($n=11$)	MS ($n=21$)
Caudate	1356 \pm 220	1413 \pm 211
Putamen	1460 \pm 290	1536 \pm 436
Thalamus	2126 \pm 443	2083 \pm 526

Volumes differed between the Reference and all four automated methods for all structures (all $p < 0.01$), but there were no differences between the volumes for pairs of automated methods

structures. The manual labels were combined by majority voting to create the reference segmentation. An evaluation at the voxel level showed similar numbers of voxels segmented by only a single rater in both MS and controls, indicating that there was no greater disagreement between the raters for MS patients compared to controls, see Table 4.

Performance of automated methods

Volumetric agreement

DGM volumes of the reference and automatic segmentations were compared. In Fig. 2, an example T1 image is shown along with the corresponding segmentation of reference and automated method. Figure 3 and Table 2 show the volumetric and spatial agreement between reference and automated

method. Over the total dataset ($n=32$) automated average volumes all differed from reference segmentations: caudate and putamen volumes were on average underestimated by all automated method, while thalamus volumes were overestimated by FSL-FIRST and FreeSurfer and underestimated by GIF and volBrain (all $p < 0.01$). Despite these systematic differences, ICC for FSL-FIRST, FreeSurfer and volBrain varied between good ($0.60 \leq \text{ICC} < 0.75$) and excellent ($\text{ICC} \geq 0.75$) and for GIF from fair ($0.40 \leq \text{ICC} < 0.60$) to excellent (Table 3).


Spatial agreement

The DSC between reference and automatic segmentations were assessed. Figure 4, Table 5 show the DSC for both controls and patients. For thalamus, all the DSC were significantly lower for patients compared to controls ($p < 0.05$). For putamen, this was the case for FreeSurfer and GIF, for both left and right hemisphere. The volumes were, however, different in all cases, mostly lower in MS. For the caudate, only a significant difference in DSC between controls and patients was found in the right hemisphere for FreeSurfer and Gif. In all cases, a large variation was observed for patients compared to controls, see Fig. 4.

Relation with pathology

Higher WM lesion load was associated with a lower performance of the automated method: total WM lesion load

**Fig. 2** T1 weighted images and segmentation of majority voting, FSL-FIRST, FreeSurfer, GIF and volBrain. Segmentations of both left and right hemisphere and for all three structures; caudate, putamen and thalamus



◀**Fig. 3** Majority voting segmentation volume and volume by automatic segmentation are given for each deep gray matter structure and segmentation method. Volumes are given in milliliters

was negatively correlated with DSC for all method (Table 6 and Fig. 5). The correlation was moderate to strong for all structures and for all methods and both sides ($|r| > 0.2$), however, not all were significant, see Table 6. The regional WM lesion load, i.e., that located within 10 mm of the structure, was also negatively correlated with DSC (Table 6), however, these correlations ranged from weak to moderate for putamen and thalamus and for caudate from moderate too strong.

Both NBV and the volume of the structure of interest itself were positively correlated with DSC (Table 6). The correlations between NBV and DSC were often not significant and ranged between weak and strong for the different structures, methods and sides. The correlations between the volume of the structure and DSC were often significant. Only the correlation of DSC and volume measured on left caudate with GIF and on left thalamus with FreeSurfer were not significant. The correlations ranged for the putamen, thalamus and right caudate from moderate too strong and for left thalamus from weak too strong.

To overcome the effect of lesions, two lesion-filling methods (LST-LF and LEAP) were used. Two-way ANOVA analysis per hemisphere, per method and DGM structure showed no significant difference in segmentation volume and DSC for both lesion filling methods compared to native (non-filled) patients images (see Supplementary Fig. 1 and Supplementary Table 5). Moreover, Student's *t* test showed no significant difference in segmentation volume or DSC for either of the filling methods compared to native patient images (Table 7).

Discussion

Using a systematic and objective evaluation against a consensus of manual segmentations in a multi-center dataset, this study provides evidence that automated DGM segmentation methods performed worse on brain scans of MS patients than on those of healthy controls. Higher lesion volumes were associated with poorer DGM segmentation performance.

The accuracy of DGM segmentations is not an academic question but also has great clinical importance. Clinical and cognitive deterioration in MS have been linked to brain and GM atrophy [5, 23, 24], and several treatments are now available that are able to reduce brain atrophy rates in MS [25–28]. Accurate measurement of the volumes of DGM structures in MS is becoming especially important, because of the strong relation of DGM atrophy with cognitive impairment (1,5). This study reveals that existing

DGM segmentation methods perform not as accurate in MS patients as in controls, as reflected by the lower DSC (overlap) scores. This implies that the results may incorporate increased random variability and bias when applied to MS cases and should be interpreted with great caution. In the future, methodological improvements are required to achieve better performance in MS.

Only a limited number of studies directly investigated the performance of DGM segmentation methods when applied to MS. Derakhshan et al. (2010) evaluated six automated segmentation method for GM atrophy on T1 MR images of three MS patients. They concluded that severe shortcomings are present in the segmentation of DGM structures [1]. The current study extends those findings substantially by investigating a multi-center dataset comprising 21 MS subjects and 11 controls using full three-dimensional manual segmentations of three DGM structures bilaterally. Importantly, using this dataset we were able to objectively compare several widely applied automated segmentation techniques in a multi-center setting. By selecting from previously acquired data a subset that maximized the number of scanners and the number of progressive patients, we were able to demonstrate quantitatively that this performance impairment exists in MS patients with a relatively long disease duration and/or progressive course. It would next be important to confirm this independently, as well as to investigate if the effect already occurs in early MS or CIS, given that DGM atrophy already occurs at those early stages [29].

To obtain insights that could aid in amending the impairment of segmentation performance, we investigated several possible causes. One important candidate reason for the reduced accuracy of DGM segmentation in MS is formed by the focal WM lesions. Previous work on whole-brain total GM volume measurement has shown that MS WM lesions affect the GM volume measurement for a number of different packages [6–9, 30]. Similarly, the presence of local or overall brain atrophy or diffusions damage could affect the performance of segmentation methods [31]. The precise mechanism behind these deteriorating effects may differ between packages but could include effects on image intensity histograms, image registration and non-brain tissue removal [5]. Therefore, we investigated whether total lesion load, regional lesion load, NBV and the volume of the structure itself were related to the performance of the automated DGM segmentation method. The strongest association with poorer accuracy in MS cases compared to healthy controls was observed for total WM lesion load. Higher regional lesions load and lower total and local brain volumes were also associated with poorer performance, but less strongly. It should be mentioned that the small size of regional lesion load—which is confined to a narrow region around the structure of interest—and the relatively small number of MS patients may have hampered our ability to detect this




Fig. 4 Dice similarity coefficients between segmentations from majority voting and each automated method per DGM structure for both healthy controls (HC) and patients (green)

Table 5 For all structures and hemispheres the spatial overlap between the “Gold standard” and the automated segmentation methods for both control and patients group

Method	Caudate nucleus			
	Controls ($N=11$)		Patients ($N=21$)	
	Left	Right	Left	Right
FSL-FIRST	0.84 ± 0.44	0.87 ± 0.03	0.86 ± 0.24	0.86 ± 0.04
FreeSurfer	0.85 ± 0.02	0.85 ± 0.02	0.82 ± 0.06	0.83 ± 0.05
GIF	0.85 ± 0.02	0.86 ± 0.01	0.83 ± 0.05	0.83 ± 0.06
volBrain	0.88 ± 0.02	0.88 ± 0.02	0.87 ± 0.03	0.87 ± 0.02
	Putamen			
	Controls ($N=11$)		Patients ($N=21$)	
	Left	Right	Left	Right
FSL-FIRST	0.89 ± 0.03	0.88 ± 0.04	0.88 ± 0.03	0.87 ± 0.04
FreeSurfer	0.89 ± 0.01	0.88 ± 0.01	0.85 ± 0.05	0.86 ± 0.03
GIF	0.82 ± 0.02	0.83 ± 0.01	0.80 ± 0.03	0.81 ± 0.02
volBrain	0.89 ± 0.01	0.89 ± 0.01	0.88 ± 0.02	0.89 ± 0.02
	Thalamus			
	Controls ($N=11$)		Patients ($N=21$)	
	Left	Right	Left	Right
FSL-FIRST	0.86 ± 0.02	0.86 ± 0.03	0.81 ± 0.05	0.81 ± 0.06
FreeSurfer	0.85 ± 0.02	0.86 ± 0.02	0.83 ± 0.05	0.83 ± 0.05
GIF	0.80 ± 0.01	0.77 ± 0.02	0.77 ± 0.03	0.75 ± 0.04
volBrain	0.87 ± 0.01	0.87 ± 0.01	0.84 ± 0.05	0.84 ± 0.04

The spatial overlap is given as the mean \pm standard deviation of the Dice Similarity Coefficient. Values of patients are bold if they are significantly different from those of controls (p -value < 0.05). N =amount of subjects

association. Moreover, we should mention that the relation between the volume of the structure and the performance of the automated DGM segmentation methods could also result from the artifact that the performance is dependent on the volume (greater volume could result in higher DSC). Therefore, the positive relationship should be studied in more detail for a better understanding of this effect.

While the accuracy of the segmentation was the most important focus of the present work, the accuracy of the resulting volumes may be considered at least equally important from a clinical viewpoint. Here to, systematic differences were observed between the automated methods and the reference measurements. We also saw a difference between the volumes obtained from different methods for each structure separately. The automated methods underestimated volumes of caudate and putamen while the volume of the thalamus was generally overestimated. This difference could be related to the different anatomical definitions used in the manual standard and the automated methods. One specific example is the question of whether the lateral geniculate nuclei bodies should be included or excluded when segmenting the thalamus [32]. The differences for the structures

could also be indirectly related to disease effects: due to the anatomical location of the structures, some brain regions are more prone to contain lesions than others or could be more affected by regional atrophy (both of which could impair DGM segmentation). A study with more patients and a more diverse lesion load could give more insight if the automated method performs differently on DGM structures. Moreover, a study on spatial patterns on the DGM structures could also give more insight into the performance of the methods.

It has been suggested that filling lesions increases the accuracy of total GM segmentation, and we also expected an improvement of DGM segmentation after lesions filling [6, 30, 33]. However, we measured no difference in the performance of the automated method compared to manual segmentation after filling lesions. This is similar to the results reported in 2014 by Popescu et al. for filling with FLS-lesion filling and LEAP and segmentation with FSL-First for multiple DGM structures (e.g. thalamus, putamen, caudate nucleus, brainstem) (7). Therefore, it seems that lesion filling increases the accuracy of total GM segmentation, however, it does not increase the accuracy of DGM segmentation. Our hypothesis on this is that an underlying

Table 6 Spearman correlation between the dice similarity index and lesion load (LL), regional lesion load (RLL), normalized brain volume (NBV) and volume of region of interest (ROIV)

Method	Left caudate				Right caudate			
	LL	RLL	NBV	ROIV	LL	RLL	NBV	ROIV
N=21								
FSL-FIRST	-0.31	-0.52*	-0.88	0.45*	-0.33	-0.41	0.36	0.53**
FreeSurfer	-0.60**	-0.49*	0.20	0.47**	-0.57**	-0.62*	0.25	0.37*
GIF	-0.68**	-0.57**	0.25	0.17	-0.57**	-0.63*	0.34	0.38*
volBrain	-0.34	-0.43	0.17	0.61**	-0.57**	-0.58**	0.18	0.82**
	Left Putamen				Right Putamen			
	LL	RLL	NBV	ROIV	LL	RLL	NBV	ROIV
FSL-FIRST	-0.56**	-0.30**	0.69**	0.72**	-0.69**	-0.80**	0.43	0.62**
FreeSurfer	-0.26	-0.45	0.08	0.74**	-0.56**	-0.20	0.23	0.37**
GIF	-0.26	-0.25	0.52	0.65**	-0.54*	-0.50	0.40	0.59**
volBrain	-0.39	-0.09	0.43	0.56**	-0.34	-0.68**	0.44*	0.65**
	Left Thalamus				Right Thalamus			
	LL	RLL	NBV	ROIV	LL	RLL	NBV	ROIV
FSL-FIRST	-0.46*	-0.16	0.36	0.54**	-0.52*	-0.27	0.29	0.42*
FreeSurfer	-0.53*	-0.30	0.30	0.26	-0.49*	-0.38	0.46*	0.64*
GIF	-0.42	-0.43	0.18	0.52**	-0.23	-0.29	0.18	0.44*
volBrain	-0.30	-0.16	0.45*	0.48**	-0.31	-0.26	0.41	0.63**

Correlation is measured for all structures, hemispheres and automated segmentation software. With α for * <0.05 and ** <0.01 for significant spearman correlation. N =amount of subjects


**Fig. 5** Dice similarity coefficients versus lesion load, represented per DGM structure and segmentation method and left (blue) and right (green) hemisphere

Table 7 For all structures, hemispheres and automated segmentation method the *p*-value of students *t* test between dice similarity index of non-filled and filled T1 images before applying automated segmentation method

Method	Left Caudate		Right Caudate	
	LEAP	LST-filling	LEAP	LST-filling
<i>N</i> =21				
FSL-FIRST	0.70	0.90	0.79	0.73
FreeSurfer	0.73	0.75	0.16	0.56
GIF	0.84	0.76	0.78	0.54
volBrain	0.75	0.84	0.84	0.79
	Left Putamen		Right Putamen	
	LEAP	LST-filling	LEAP	LST-filling
FSL-FIRST	0.55	0.92	0.91	0.97
FreeSurfer	0.89	0.56	0.89	0.97
GIF	0.36	0.86	0.25	0.90
volBrain	0.86	0.95	0.79	0.51
	Left Thalamus		Right Thalamus	
	LEAP	LST-filling	LEAP	LST-filling
FSL-FIRST	0.56	0.95	0.63	0.95
FreeSurfer	0.85	0.87	0.86	0.98
GIF	0.84	0.96	0.94	0.88
volBrain	0.98	0.98	0.78	0.89

Filling is done with LEAP and LST

N= amount of subjects

factor such as regional atrophy or GM lesion load or a combination of the pathology aspects (e.g. lesion load, atrophy, NAWM, diffusion damage) could be a cause. It should be mentioned that the lesions were manually outlined on either T2/PD images or FLAIR images, potentially leading to differences in the lesion segmentations that could have affected our results. However, after dividing the group into two different sets the same effects were visible as in the complete group, though less significant, as expected for the smaller group sizes.

Moreover, we suggest a study on the effect of WM-GM contrast-to-noise ratio which might cause this effect. As MS pathology affects both the WM and GM, resulting in more variation in the WM and GM signal, it is possible that the WM-GM contrast ratio is changed. Ratio could be changed due to iron change or damage of WM and/or GM [34]. Westlye et al. (2009) showed in Alzheimer's Disease (AD) that cortical thickness in subjects with regionally reduced tissue contrast was overestimated compared to subjects without reduces tissue contrast. They indicate that the overestimation is related to alterations in myelin density and water compartment close to the WM. Moreover, adjusting for local variability in tissue contrast could correct the overestimation [35]. Therefore, further studies should investigate this in MS and, moreover, other possible causes (e.g. diffuse signal

changes, the effect of image processing) should be investigated as well.

Furthermore, as it is important to have segmentation with accurate spatial level for correct localization and shape, future research could take a more in-depth approach regarding shape analysis e.g. quantitative vertex displacement analysis [36]. This analysis enables the finding of vertices which have a significantly different shape from the reference and would be of added value in unraveling why some packages are outperforming others.

In conclusion, the performance of four state-of-the-art automated DGM segmentation method is impaired in MS, which warrants caution in interpreting DGM volumes both in group studies and in individual patients. Poorer accuracy was associated with higher WM lesion load and smaller global-local brain volumes, but the mechanism is not yet understood. Remarkably, the impaired performance was not improved by lesion-filling. More research is needed to understand the underlying causes of reduced accuracy and then eliminate their effects.

Acknowledgements A. de Sitter is employed on a project sponsored by a research grant from Teva Pharmaceuticals (grant to H. Vrenken and F. Barkhof). T. Verhoeven has no disclosures. Y. Liu has no disclosures related to this paper. J. Burggraaff has no disclosures. J. Simoes has no disclosures. S. Ruggieri received fees as an invited speaker or travel expenses for attending the meeting from Biogen, Merck-Serono,

Teva, Sanofi, Novartis. M. Palotai has no disclosures. I. Brouwer is partly employed on projects sponsored by research grants from Teva Pharmaceuticals and Novartis Pharma (grants to H. Vrenken and F. Barkhof). A. Versteeg has no disclosures. V. Wottschel has no disclosures related to this paper. S. Ropele has no disclosures related to this paper. M.A. Rocca received speakers' honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva, Merck Serono, Roche and Celgene and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. C. Gasperini received fees as a speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, and Merck-Serono, and received a grant for research by Teva. A. Gallo has no disclosures related to this paper. M.C. Yiannakas has no disclosures. A. Rovira has no disclosures related to this paper. C. Enzinger has no disclosures related to this paper. M. Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). N. De Stefano has no disclosures related to this paper. L. Kappos has no disclosures related to this paper. J. L. Frederiksen declares personal fees from Biogen Idec, Merck Serono and Sanofi-Aventis, participation in scientific advisory boards for Almiral, Genzyme and Novartis, personal fees (speaker honoraria) from Biogen, Merck, Santhera and Teva, all unrelated to this paper. F. Barkhof has received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck Serono, Novartis, Roche, Teva, Bracco and IXICO. C.R.G. Gutmann has received support from the National Multiple Sclerosis Society, the International Progressive Multiple Sclerosis Alliance, the U.S. Office for Naval Research, Mobilengine (free use of platform and programming by Mobilengine Engineers), NIH, as well as travel support from Roche Pharmaceuticals; C.R.G. owns stock in Roche, Novartis, GSK, Alnylam, Protalix Biotherapeutics, Arrowhead Pharmaceuticals, Cocrysal Pharma, Sangamo Therapeutics. H. Vrenken has received research grants from Pfizer, MerckSerono, Novartis and Teva, speaker honoraria from Novartis, and consulting fees from MerckSerono; all funds were paid directly to his Institution.

Funding There was no funding specifically for this work.

Data availability Data are not available for other research groups, because of ethical and privacy issues.

Compliance with ethical standards

Conflict of interest AdS is employed on a project sponsored by a research grant from Teva Pharmaceuticals (grant to H. Vrenken and F. Barkhof). TV has no disclosures. YL has no disclosures related to this paper. JB has no disclosures. JS has no disclosures. SR received fees as invited speaker or travel expenses for attending meeting from Biogen, Merck-Serono, Teva, Sanofi, Novartis. MP has no disclosures. IB is partly employed on projects sponsored by research grants from Teva Pharmaceuticals and Novartis Pharma (grants to HV and FB). AV has no disclosures. VW has no disclosures related to this paper. SR has no disclosures related to this paper. MAR received speakers' honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva, Merck Serono, Roche and Celgene and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. CG received fees as speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, and Merck-Serono, and received a grant for research by Teva. AG has no disclosures related to this paper. MCY has no disclosures. AR has no disclosures relat-

ed to this paper. CE has no disclosures related to this paper. MF is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). NDS has no disclosures related to this paper. LK has no disclosures related to this paper. JLF declares personal fees from Biogen Idec, Merck Serono and Sanofi-Aventis, participation in scientific advisory boards for Almiral, Genzyme and Novartis, personal fees (speaker honoraria) from Biogen, Merck, Santhera and Teva, all unrelated to this paper. FB has received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck Serono, Novartis, Roche, Teva, Bracco and IXICO. CRGG has received support from the National Multiple Sclerosis Society, the International Progressive Multiple Sclerosis Alliance, the U.S. Office for Naval Research, Mobilengine (free use of platform and programming by Mobilengine Engineers), NIH, as well as travel support from Roche Pharmaceuticals; C.R.G. owns stock in Roche, Novartis, GSK, Alnylam, Protalix Biotherapeutics, Arrowhead Pharmaceuticals, Cocrysal Pharma, Sangamo Therapeutics. HV has received research grants from Pfizer, MerckSerono, Novartis and Teva, speaker honoraria from Novartis, and consulting fees from MerckSerono; all funds were paid directly to his Institution.

Ethical standards The local ethical review boards had approved the original study. All patients and controls provided written informed consent for participating in the original study and for the use of their brain MRI-scans.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Derakhshan M, Caramanos Z, Giacomini PS, Narayanan S, Maranzano J, Francis SJ et al (2010) Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. *Neuroimage*. 52(4):1261–1267. <https://doi.org/10.1016/j.neuroimage.2010.05.029> **Epub 2010/05/21**
2. Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M et al (2018) Progression of regional grey matter atrophy in multiple sclerosis. *Brain* 141(6):1665–1677. <https://doi.org/10.1093/brain/awy088> **Epub 2018/05/10**
3. Modica CM, Bergsland N, Dwyer MG, Ramasamy DP, Carl E, Zivadinov R et al (2016) Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. *Mult Scler*. 22(1):36–42. <https://doi.org/10.1177/1352458515579443> **Epub 2015/04/30**
4. Schoonheim MM, Ciccarelli O (2018) The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.

- Neurology. 90(15):677–678. <https://doi.org/10.1212/WNL.00000000000005279> **Epub 2018/03/16**
5. Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M et al (2018) Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. *Neuroimage Clin*. 19:466–475. <https://doi.org/10.1016/j.nicl.2018.04.023> **Epub 2018/07/10**
 6. Popescu V, Ran NC, Barkhof F, Chard DT, Wheeler-Kingshott CA, Vrenken H (2014) Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. *Neuroimage Clin* 4:366–373. <https://doi.org/10.1016/j.nicl.2014.01.004>
 7. Battaglini M, Jenkinson M, De Stefano N (2012) Evaluating and reducing the impact of white matter lesions on brain volume measurements. *Hum Brain Mapp* 33(9):2062–2071. <https://doi.org/10.1002/hbm.21344> **Epub 2011/09/02**
 8. Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA (2010) Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. *J Magn Reson Imaging*. 32(1):223–228. <https://doi.org/10.1002/jmri.22214> **Epub 2010/06/25**
 9. Nakamura K, Fisher E (2009) Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. *Neuroimage* 44(3):769–776. <https://doi.org/10.1016/j.neuroimage.2008.09.059> **Epub 2008/11/15**
 10. Patenaude B, Smith SM, Kennedy DN, Jenkinson M (2011) A Bayesian model of shape and appearance for subcortical brain segmentation. *Neuroimage* 56(3):907–922. <https://doi.org/10.1016/j.neuroimage.2011.02.046> **Epub 2011/03/01**
 11. Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis I. Segmentation and surface reconstruction. *Neuroimage* 9(2):179–194. <https://doi.org/10.1006/nimg.1998.0395> **Epub 1999/02/05**
 12. Cardoso MJ, Modat M, Wolz R, Melbourne A, Cash D, Rueckert D et al (2015) Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. *IEEE Trans Med Imaging* 34(9):1976–1988. <https://doi.org/10.1109/TMI.2015.2418298> **Epub 2015/04/17**
 13. Manjon JV, Coupe P (2016) volBrain: an online MRI brain volumetry system. *Front Neuroinform*. 10:30. <https://doi.org/10.3389/fninf.2016.00030> **Epub 2016/08/12**
 14. Rocca MA, Valsasina P, Hulst HE, Abdel-Aziz K, Enzinger C, Gallo A et al (2014) Functional correlates of cognitive dysfunction in multiple sclerosis: a multicenter fMRI Study. *Hum Brain Mapp* 35(12):5799–5814. <https://doi.org/10.1002/hbm.22586>
 15. Ropele S, Kilsdonk ID, Wattjes MP, Langkammer C, de Graaf WL, Frederiksen JL et al (2014) Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. *Mult Scler* 20(13):1692–1698. <https://doi.org/10.1177/1352458514531085>
 16. Schmidt P, Gaser C, Arsic M, Buck D, Forschler A, Berthele A et al (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. *Neuroimage* 59(4):3774–3783. <https://doi.org/10.1016/j.neuroimage.2011.11.032> **Epub 2011/11/29**
 17. Coupe P, Manjon JV, Fonov V, Pruessner J, Robles M, Collins DL (2011) Patch-based segmentation using expert priors: application to hippocampus and ventricle segmentation. *Neuroimage* 54(2):940–954. <https://doi.org/10.1016/j.neuroimage.2010.09.018> **Epub 2010/09/21**
 18. Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. *J Comput Assist Tomo* 25(3):466–475. <https://doi.org/10.1097/00004728-200105000-00022>
 19. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. *Neuroimage* 17(1):479–489 **Epub 2002/12/17**
 20. Zijdenbos AP, Dawant BM, Margolin RA, Palmer AC (1994) Morphometric analysis of white matter lesions in MR images: method and validation. *IEEE Trans Med Imaging*. 13(4):716–724. <https://doi.org/10.1109/42.363096> **Epub 1994/01/01**
 21. Tukey J (1952) *Statistical Methods for Research Workers*. *Econometrica* 20(3):511–512. <https://doi.org/10.2307/1907425>
 22. Corder GW, Foreman DI (2009) *Nonparametric statistics for non-statisticians: a step-by-step approach*. Wiley, Hoboken
 23. Benedict RHB, Hulst HE, Bergsland N, Schoonheim MM, Dwyer MG, Weinstock-Guttman B et al (2013) Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. *Mult Scler J* 19(11):1478–1484. <https://doi.org/10.1177/1352458513478675>
 24. Chard DT, Brex PA, Ciccarelli O, Griffin CM, Parker GJ, Dalton C et al (2003) The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. *J Neurol Neurosurg Psychiatry* 74(11):1551–1554. <https://doi.org/10.1136/jnnp.74.11.1551> **Epub 2003/11/18**
 25. Calabrese PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol* 13(6):545–556. [https://doi.org/10.1016/S1474-4422\(14\)70049-3](https://doi.org/10.1016/S1474-4422(14)70049-3)
 26. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet* 380(9856):1829–1839. [https://doi.org/10.1016/S0140-6736\(12\)61768-1](https://doi.org/10.1016/S0140-6736(12)61768-1) **Epub 2012/11/06**
 27. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med* 376(3):221–234. <https://doi.org/10.1056/NEJMoa1601277> **Epub 2016/12/22**
 28. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F et al (2016) Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. *Cochrane Database Syst Rev* 11:CD009333. <https://doi.org/10.1002/14651858.CD009333.pub3> **Epub 2016/11/24**
 29. Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ et al (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. *Ann Neurol* 83(2):210–222. <https://doi.org/10.1002/ana.25145> **Epub 2018/01/14**
 30. Guo C, Ferreira D, Fink K, Westman E, Granberg T (2019) Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis. *Eur Radiol* 29(3):1355–1364. <https://doi.org/10.1007/s00330-018-5710-x> **Epub 2018/09/23**
 31. de Bresser J, Portegies MP, Leemans A, Biessels GJ, Kappelle LJ, Viergever MA (2011) A comparison of MR based segmentation methods for measuring brain atrophy progression. *Neuroimage* 54(2):760–768. <https://doi.org/10.1016/j.neuroimage.2010.09.060> **Epub 2010/10/05**
 32. Power BD, Wilkes FA, Hunter-Dickson M, van Westen D, Santillo AF, Walterfang M et al (2015) Validation of a protocol for manual segmentation of the thalamus on magnetic resonance imaging scans. *Psychiatry Res* 232(1):98–105. <https://doi.org/10.1016/j.psychres.2015.02.001> **Epub 2015/03/11**
 33. Magon S, Gaetano L, Chakravarty MM, Lerch JP, Naegelin Y, Stippich C et al (2014) White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study. *BMC Neurosci* 15:106. <https://doi.org/10.1186/1471-2202-15-106> **Epub 2014/09/10**
 34. Yablonskiy DA, Luo J, Sukstanskii AL, Iyer A, Cross AH (2012) Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis. *Proc Natl Acad Sci USA* 109(35):14212–14217. <https://doi.org/10.1073/pnas.1206037109> **Epub 2012/08/15**

35. Westlye LT, Walhovd KB, Dale AM, Espeseth T, Reinvang I, Raz N et al (2009) Increased sensitivity to effects of normal aging and Alzheimer's disease on cortical thickness by adjustment for local variability in gray/white contrast: a multi-sample MRI study. *Neuroimage* 47(4):1545–1557. <https://doi.org/10.1016/j.neuroimage.2009.05.084> Epub 2009/06/09
36. Kim H, Mansi T, Bernasconi A, Bernasconi N (2011) Vertex-wise shape analysis of the hippocampus: disentangling positional differences from volume changes. *Med Image Comput Comput Assist Interv* 14(Pt 2):352–359. https://doi.org/10.1007/978-3-642-23629-7_43 Epub 2011/10/15

Affiliations

Alexandra de Sitter¹ · Tom Verhoeven¹ · Jessica Burggraaff² · Yaou Liu¹ · Jorge Simoes¹ · Serena Ruggieri^{3,4} · Miklos Palotai⁵ · Iman Brouwer¹ · Adriaan Versteeg¹ · Viktor Wottschel¹ · Stefan Ropele⁶ · Mara A. Rocca^{7,8} · Claudio Gasperini⁴ · Antonio Gallo⁹ · Marios C. Yiannakas¹⁰ · Alex Rovira¹¹ · Christian Enzinger¹² · Massimo Filippi^{7,8,13,14} · Nicola De Stefano¹⁵ · Ludwig Kappos¹⁶ · Jette L. Frederiksen¹⁷ · Bernard M. J. Uitdehaag² · Frederik Barkhof^{1,18} · Charles R. G. Guttmann⁵ · Hugo Vrenken¹ · the MAGNIMS Study Group

¹ Department of Radiology and Nuclear Medicine, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

² Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands

³ Department of Human Neurosciences, “Sapienza” University of Rome, Rome, Italy

⁴ Department of Neurosciences, San Camillo Forlanini Hospital, Rome, Italy

⁵ Center for Neurological Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁶ Department of Neurology, Medical University of Graz, Graz, Austria

⁷ Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, Milan, Italy

⁸ Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁹ Division of Neurology and MRI Research Center, Department of Medical, Surgical, Neurologic, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy

¹⁰ Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK

¹¹ Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital Universitari Vall D'Hebron, Autonomous University of Barcelona, Barcelona, Spain

¹² Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology Medical, University of Graz, Graz, Austria

¹³ Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹⁴ Vita-Salute San Raffaele University, Milan, Italy

¹⁵ Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy

¹⁶ Department of Neurology, University Hospital, Kantonsspital, Basel, Switzerland

¹⁷ Department of Neurology, Glostrup University Hospital Copenhagen, Copenhagen, Denmark

¹⁸ Institutes of Neurology and Healthcare Engineering, UCL London, London, UK